Evidence map›Paper›PMID 28898283›Full record

Trial reportPLoS medicine2017

Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial.

Benedict Weobong, Helen A Weiss, David McDaid, Daisy R Singla, Steven D Hollon, Abhijit Nadkarni, A-La Park, Bhargav Bhat, Basavraj Katti, Arpita Anand and 9 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05944926 (Improving Outcomes in Depression in Primary Care in a Low Resource Setting), which is not on this map. Cited by 62 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05944926 phase3active not recruitingnot on this mapstarted 2024, after this paper: background citation

Improving Outcomes in Depression in Primary Care in a Low Resource Setting

TypeinterventionalSponsorHarvard Medical School (HMS and HSDM)Ran2024 to 2026Enrolled1,500ConditionsDepression, Depressive DisorderArmsHealthy Activity Program (HAP), Antidepressant medication (fluoxetine)
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Behavioural activation therapy for depression in adults.The Cochrane database of systematic reviews · 2020
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Benedict WeobongCentre for Global Mental Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Helen A WeissMRC Tropical Epidemiology Group, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0003-3547-7936
David McDaidPersonal Social Services Research Unit, London School of Economics and Political Science, London, United Kingdom.ORCID http://orcid.org/0000-0003-0744-2664
Daisy R SinglaDepartment of Psychiatry, Sinai Health Network, University of Toronto, Toronto, Ontario, Canada.
Steven D HollonDepartment of Psychology, Vanderbilt University, Nashville, Tennessee, United States of America.
Abhijit NadkarniCentre for Global Mental Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
A-La ParkPersonal Social Services Research Unit, London School of Economics and Political Science, London, United Kingdom.
Bhargav BhatSangath, Socorro, Goa, India.
Basavraj KattiSangath, Socorro, Goa, India.ORCID http://orcid.org/0000-0002-9824-6193
Arpita AnandSangath, Socorro, Goa, India.
Sona DimidjianDepartment of Psychology and Neuroscience, University of Colorado, Boulder, Colorado, United States of America.
Ricardo ArayaCentre for Global Mental Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0002-0420-5148
Michael KingDivision of Psychiatry, Faculty of Brain Sciences, University College London, London, United Kingdom.
Lakshmi VijayakumarSNEHA, Voluntary Health Services, University of Melbourne, Melbourne, Victoria, Australia.
G Terence WilsonDepartment of Psychology, School of Arts and Sciences, Rutgers University, New Brunswick, New Jersey, United States of America.
Richard VellemanSangath, Socorro, Goa, India.
Betty R KirkwoodCentre for Global Mental Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0001-5274-6072
Christopher G FairburnDepartment of Psychiatry, University of Oxford, Oxford, United Kingdom.ORCID http://orcid.org/0000-0002-9673-9795
Vikram PatelCentre for Global Mental Health, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID http://orcid.org/0000-0003-1066-8584

Funding

Medical Research Council MR/K012126/1Wellcome Trust 091834
6 · The paper itself

Abstract

backgroundThe Healthy Activity Programme (HAP), a brief behavioural intervention delivered by lay counsellors, enhanced remission over 3 months among primary care attendees with depression in peri-urban and rural settings in India. We evaluated the sustainability of the effects after treatment termination, the cost-effectiveness of HAP over 12 months, and the effects of the hypothesized mediator of activation on clinical outcomes. METHODS AND

findingsPrimary care attendees aged 18-65 years screened with moderately severe to severe depression on the Patient Health Questionnaire 9 (PHQ-9) were randomised to either HAP plus enhanced usual care (EUC) (n = 247) or EUC alone (n = 248), of whom 95% completed assessments at 3 months, and 91% at 12 months. Primary outcomes were severity on the Beck Depression Inventory-II (BDI-II) and remission on the PHQ-9. HAP participants maintained the gains they showed at the end of treatment through the 12-month follow-up (difference in mean BDI-II score between 3 and 12 months = -0.34; 95% CI -2.37, 1.69; p = 0.74), with lower symptom severity scores than participants who received EUC alone (adjusted mean difference in BDI-II score = -4.45; 95% CI -7.26, -1.63; p = 0.002) and higher rates of remission (adjusted prevalence ratio [aPR] = 1.36; 95% CI 1.15, 1.61; p < 0.009). They also fared better on most secondary outcomes, including recovery (aPR = 1.98; 95% CI 1.29, 3.03; p = 0.002), any response over time (aPR = 1.45; 95% CI 1.27, 1.66; p < 0.001), higher likelihood of reporting a minimal clinically important difference (aPR = 1.42; 95% CI 1.17, 1.71; p < 0.001), and lower likelihood of reporting suicidal behaviour (aPR = 0.71; 95% CI 0.51, 1.01; p = 0.06). HAP plus EUC also had a marginal effect on WHO Disability Assessment Schedule score at 12 months (aPR = -1.58; 95% CI -3.33, 0.17; p = 0.08); other outcomes (days unable to work, intimate partner violence toward females) did not statistically significantly differ between the two arms. Economic analyses indicated that HAP plus EUC was dominant over EUC alone, with lower costs and better outcomes; uncertainty analysis showed that from this health system perspective there was a 95% chance of HAP being cost-effective, given a willingness to pay threshold of Intl$16,060-equivalent to GDP per capita in Goa-per quality-adjusted life year gained. Patient-reported behavioural activation level at 3 months mediated the effect of the HAP intervention on the 12-month depression score (β = -2.62; 95% CI -3.28, -1.97; p < 0.001). Serious adverse events were infrequent, and prevalence was similar by arm. We were unable to assess possible episodes of remission and relapse that may have occurred between our outcome assessment time points of 3 and 12 months after randomisation. We did not account for or evaluate the effect of mediators other than behavioural activation.

conclusionsHAP's superiority over EUC at the end of treatment was largely stable over time and was mediated by patient activation. HAP provides better outcomes at lower costs from a perspective covering publicly funded healthcare services and productivity impacts on patients and their families.

trial registrationISRCTN registry ISRCTN95149997.

Indexed as

AdolescentAdultAgedCost-Benefit AnalysisDelivery of Health CareFemaleFollow-Up StudiesHealth PromotionHumansIndiaMajor Depressive DisorderMaleMiddle AgedPrimary Health CarePsychiatric Status Rating ScalesPsychotherapy

Identifiers

PMID28898283
PMCPMC5595303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.